BioNTech and Pfizer get German approval for Covid-19 vaccine trial

22nd April 2020 (Last Updated April 22nd, 2020 12:52)

BioNTech and Pfizer have secured approval from the German regulatory authority,  Paul-Ehrlich-Institut, to conduct a Phase I/II clinical trial of a Covid-19 vaccine candidate.

The candidate, BioNTech’s BNT162, is intended to prevent Covid-19 infection. BioNTech and Pfizer are co-develping the vaccine programme.

Said to be the first Covid-19 vaccine trial to launch in Germany, the study is part of a global development programme.

Read the full article here